Literature DB >> 7393969

PGD2 effects on rodent behavior and EEG patterns in cats.

S G Laychock, D N Johnson, L S Harris.   

Abstract

Prostaglandin (PG) D2 was studied to determine the pharmacological effects of this PG on the central nervous system. PGD2 (0.45-4.05 mg/kg) decreased spontaneous locomotor activity in rats by as much as 66% of control, however, the neuromuscular coordination of mice, treated at the same doses of PGD2, was not impaired. PGD2 (0.05-4.05 mg/kg) also increased pentobarbital sleeping time in mice from 42% to 238% of control, in a dose-related manner. PGD2 did not prevent convulsions induced in response to electroshock or pentylenetetrazol. Cats monitored for EEG responses to PGD2 infusion displayed variable sensitivity to different doses (16-3000 microgram) of drug, however, the characteristic response to PGD2 was the conversion from a uniform low voltage, fast wave pattern to high voltage, slow waves. Cats administered PGD2 were sedated and sometimes catatonic, and displayed brief periods of hypotension, bradycardia, diarrhea, analgesia and hyperthermia at higher doses of the drug. Thus, PGD2 possesses sedative properties in rodents and cats and may have a role in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7393969     DOI: 10.1016/0091-3057(80)90161-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  11 in total

1.  Sleep and immunity: A growing field with clinical impact.

Authors:  Mark R Opp; James M Krueger
Journal:  Brain Behav Immun       Date:  2015-04-04       Impact factor: 7.217

2.  Role of the L-PGDS-PGD2-DP1 receptor axis in sleep regulation and neurologic outcomes.

Authors:  Abdullah Shafique Ahmad; Haneen Ottallah; Carolina B Maciel; Michael Strickland; Sylvain Doré
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

3.  The antinociceptive effect of intracerebroventricularly administered prostaglandin D2 in the rat.

Authors:  S K Bhattacharya
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Effects of intracerebroventricular administration of prostaglandin D2 on behaviour, blood pressure and body temperature as compared to prostaglandins E2 and F2 alpha.

Authors:  U Förstermann; R Heldt; G Hertting
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  Protective effect of prostaglandins D2, E1 and I2 against cerebral hypoxia/anoxia in mice.

Authors:  Y Masuda; Y Ochi; Y Ochi; T Karasawa; N Hatano; T Kadokawa; M Shimizu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

6.  Sedation produced by prostaglandins is not a nonspecific fatty acid effect.

Authors:  E B Holingsworth; G A Patrick
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Decreased hypothalamic prostaglandin D2 and prostaglandin E2 contents during isoflurane anaesthesia in rats.

Authors:  T Sato; I Araki; T Kushikata; H Ohkawa; H Ishihara; A Matsuki
Journal:  Can J Anaesth       Date:  1995-11       Impact factor: 5.063

8.  Autoradiographic localization of a binding protein(s) specific for prostaglandin D2 in rat brain.

Authors:  A Yamashita; Y Watanabe; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

9.  Prostaglandin D2 inhibits pentylenetetrazole-induced convulsions in rats by a serotonin-mediated mechanism.

Authors:  S K Bhattacharya; S S Parmar
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

10.  Prostaglandins and central serotonergic activity in the rat.

Authors:  S K Bhattacharya
Journal:  Pharm Res       Date:  1985-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.